Overview

Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum

Status:
Recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

It still unclear how SARS-CoV-2 affects pregnant women and their offspring, as well as which factors may influence obstetrical disease and outcomes, including the timing of maternal viral exposure by gestational age, the effects of parity, age, host immune responses, coexisting medical and obstetrical conditions and the effects of treatment regimens. While further information is gathered, based on the existing evidence from other infections causing pneumonia, pregnant women should be considered to be at high risk for developing severe infection during the current COVID-19 epidemic. Results from clinical trials with HCQ in nonpregnant adults may not be directly extrapolated to pregnant women given the special features of the pregnancy status. Thus, clinical research is urgently needed to improve the care and reduce the risk of poor pregnancy outcomes of women in this and in future epidemics.

Phase:

Phase 3

Details

Lead Sponsor:

Barcelona Institute for Global Health

Collaborators:

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Fundación de investigación HM
Hospital Clinic of Barcelona
Hospital del Mar
Hospital General de Segovia
Hospital Sant Joan de Deu
Hospital Universitario Fundación Alcorcón
Hospital Universitario Infanta Leonor
Institut Català de la Salut
University Hospital of Torrejon

Treatments:

Hydroxychloroquine